Furthermore, it will be interesting to extend this and future studies into EBV-positive non-NPC cell lines, such as gastric tumor cells SNU719, NCC-24, and AGS, or Raji B cells to examine if using P4, BRRF1, and/or IL-22 can have broad application to successfully induce BTN2A1 to complement combined anticancer therapy using Vγ9Vδ2 T cells. This evidence concerns the gene BTN2A1 and nasopharyngeal carcinoma.